Project Grant R01DK144338
- Federal Project Grant Award Summary The University of Colorado-Denver received a $468,000 Project Grant award dated July 24, 2025, from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). This award, with a completion date of June 30, 2027, funds a research initiative examining weight loss maintenance mechanisms following dietary interventions. The project extends an ongoing one-year dietary weight loss intervention by adding...
- Federal Grant Award Summary The University of Minnesota received a $759,944 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded on March 6, 2026, with a completion date of February 28, 2031. This clinical trial research initiative will develop and evaluate a biologically-based obesity prevention intervention targeting older adolescents and young adults...
- Federal Grant Award Summary The University of Colorado-Denver received a $250,401 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded July 23, 2025, with completion targeted for November 30, 2026. This research initiative investigates the mechanisms by which amyloid-beta (Aβ) peptide disrupts synaptic nanoarchitecture in Alzheimer's disease...
- Federal Project Grant Award Summary The University of Colorado-Denver received a $780,000 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective September 1, 2025, through June 30, 2030. The award funds fundamental research examining the molecular function and substrate specificity of palmitoyltransferases (PATs)—a family of 24 enzymes in mammals that regulate behavioral responses...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant of $169,225 (Award Date: July 1, 2026; Ultimate Completion Date: April 30, 2031) under the Cardiovascular Diseases Research program (CFDA 93.837) to The Regents of the University of Colorado, doing business as University of Colorado-Denver, to conduct research on obesity interventions in preschool-aged children. Dr. Rochelle Cason-Wilkerson, the principal investigator, will lead the Targeted...
- Federal Project Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded $248,965 to The Regents of the University of Colorado-Denver through the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) for a three-year project period beginning March 1, 2026 and concluding February 28, 2029. Under the direction of Principal Investigator Dr. Catherine Cohen, PhD, RDN, the award funds a longitudinal research initiative...
- Federal Grant Award Summary The University of California, San Francisco received a $203,244 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded May 15, 2026, with completion scheduled for March 31, 2031. Under the leadership of Dr. Sujatha Seetharaman, this clinical research study—the Assessment of Body Composition in Adolescents with T2D on...
- Federal Grant Award Summary The National Institute on Drug Abuse awarded a $709,085 Project Grant to The Regents of the University of Colorado (University of Colorado-Denver) effective April 1, 2026, through January 31, 2031, under the Drug Use and Addiction Research Programs (CFDA 93.279). This implementation science research initiative will facilitate in-hospital opioid treatment program (OTP) intakes to improve linkage between hospitalized patients with opioid use disorder (OUD) and...
- Federal Grant Award Summary Colorado State University received a $453,556 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 1, 2025, through July 31, 2028. The award funds development and evaluation of a digitally enhanced cognitive-behavioral therapy (CBT) intervention designed to treat depression and improve cardiometabolic health outcomes in adolescents (ages 12-17) with elevated...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded a Project Grant of $260,086 to The Regents of the University of Colorado (University of Colorado-Denver) on July 14, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds research investigating the role of subsynaptic nanoscale architecture in inhibitory synaptic plasticity, with a project completion date of November...
Federal Grant Award Summary The University of Colorado-Denver received a $1.61 million Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), effective June 15, 2026, with a completion date of April 30, 2031. This research grant funds "The PLASTIC Trial: Investigating Brain Plasticity and GLP-1 Receptor Agonists in the Treatment of Obesity," a comparative clinical research study examining how glucagon-like peptide-1 receptor agonist (GLP-1RA) medications affect brain function and weight loss differently in adolescents versus adults. The research addresses a critical knowledge gap regarding whether GLP-1RA pharmacotherapy produces magnified or sustained neural and behavioral changes during the adolescent period of heightened neural plasticity compared to the mature adult brain. The grant supports three primary research aims: (1) investigating differential effects of GLP-1RA treatment on brain function and weight loss between adolescent and adult cohorts, (2) comparing food intake and appetite sensation responses to treatment across age groups, and (3) determining whether GLP-1RA administration during heightened neural plasticity produces sustained changes in brain function and weight compared to treatment during developmental stability. The study will generate novel evidence to inform understanding of how neuroactive pharmacotherapies targeting appetite control circuits interact with developmental brain plasticity, with potential implications for optimizing obesity treatment protocols across age groups.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.6m | 6/15/26 |